Ipamorelin / CJC-1295: Mechanism, Research, and Regulatory Status

CJC-1295 without DAC (also called Modified GRF 1-29 or mod-GRF 1-29) has a half-life of approximately 25–30 minutes. When injected it mimics the natural pulsatile GHRH pattern. CJC-1295 with DAC contains a maleimide-modified lysine that forms a covalent bond with plasma albumin, extending half-life to 6–8 days and enabling once or twice-weekly dosing. For research mimicking natural GH pulsatility, mod-GRF is typically combined with ipamorelin at each injection. The DAC version creates a more sustained, blunted GH elevation.

Reconstitute with bacteriostatic water: add diluent slowly down the vial wall, do not inject directly onto the powder cake. For ipamorelin, typical research concentration is 2–5 mg/mL. For CJC-1295 (no-DAC), 2 mg/mL is standard. The two peptides can be mixed in the same syringe for co-injection. Solutions should be clear and colorless; discard if cloudy. Store reconstituted solutions at 2–8°C; use within 28–30 days.

Older GH secretagogues like GHRP-6 and GHRP-2 stimulate GH release but also elevate ACTH, cortisol, aldosterone, and prolactin. Those are confounding factors in many research protocols, and they are associated with increased appetite (GHRP-6's notable hunger effect via ghrelin signaling in the hypothalamus). Ipamorelin is highly selective for GHS-R1a and does not affect those axes, which makes it the preferred choice for GH-specific research and allows cleaner mechanistic attribution of observed effects.

The two peptides act on separate but complementary receptor systems. CJC-1295 (GHRHR agonist) amplifies the magnitude of each GH pulse from the pituitary somatotroph. Ipamorelin (GHS-R1a agonist) increases the frequency of GH pulses and may also independently sensitize somatotrophs. Combined administration in preclinical models produces substantially greater IGF-1 elevation than either agent alone at matched doses, closely mimicking juvenile GH secretion profiles.

Both ipamorelin and CJC-1295 in lyophilized form: −20°C in sealed, desiccated vials protected from light. Lyophilized peptides are stable for 24+ months under proper conditions. Avoid freeze-thaw cycling. Keep silica desiccant packets with vials if possible. Room temperature stability is limited (days to weeks); always return to −20°C between uses.

Yes. Both ipamorelin (GH secretagogue) and CJC-1295 (GHRH analog/GH-releasing factor) are prohibited under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). This applies in all competitive sport contexts and during training periods. For non-sport research contexts, the compounds are not scheduled controlled substances in most jurisdictions but lack regulatory approval for therapeutic use.

Key research endpoints include: serum IGF-1 (most reliable surrogate for integrated GH secretion), IGFBP-3, GH pulse sampling (requires frequent blood draws), lean body mass and fat mass by DEXA, fasting insulin/glucose (for insulin resistance monitoring), and bone mineral density in longer-duration studies. GH stimulation testing before and after treatment can document whether the pituitary axis is appropriately upregulated without desensitization.

Preclinical and small human studies specifically in GH-deficient older adults show that GH secretagogues can restore more youthful GH pulsatility with fewer side effects than direct GH replacement. The elderly population is a key research demographic given age-related GH decline (somatopause). Relevant monitoring: IGF-1 should not be driven above age-specific reference ranges; glucose tolerance should be tracked, as GH-induced insulin resistance may be more pronounced in older adults.